Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...
The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...